Effects of Tepary Bean ( Phaseolus acutifolius ) Protease Inhibitor and Semipure Lectin Fractions on Cancer Cells (original) (raw)

Abstract

sparkles

AI

This research investigates the effects of Tepary Bean (Phaseolus acutifolius) protease inhibitor and semipure lectin fractions on cancer cells, highlighting their role in cancer cell proliferation and adhesion behaviors. Results indicate that the Tepary lectin fraction influences cancer cell proliferation in a dose-dependent manner, while the protease inhibitor plays a significant role in impacting cell adhesion and extracellular matrix degradation. Overall, these findings suggest that components from Tepary Bean could have potential therapeutic applications in cancer treatment.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (59)

  1. DeClerck YA, Mercurio AM, Snack MS, Chapman HA, Zutter MM, et al.: Proteases, extracellular matrix, and cancer. Am. J. Path 164, 1131-1139, 2004.
  2. Yavelow J, Findlay HT, Kennedy AR, and Troll W: Bowman-Birk soy- bean protease inhibitor as an antiarcinogen. Cancer Res 43(Suppl.), 2454S-2459S, 1983.
  3. Kennedy AR, Randner BS, and Nagasawa H: Protease inhibitors reduce the frequency of spontaneous chromosome abnormalities in cells from patients with Bloom syndrome. Proc Natl Acad Sci (USA) 81, 1827-1830, 1984.
  4. Kennedy AR: Cancer prevention by protease inhibitors. Prev Med 22, 796-811, 1993.
  5. Gueven N, Dittman K, Mayer C, and Rodemann HP: The radioprotec- tive potential of the Bowman-Birk protease inhibitor is independent of its secondary structure. Cancer Lett 125, 77-82, 1998.
  6. Kennedy AR: Chemopreventive agents: protease inhibitors. Pharmacol Ther 78, 167-209, 1998.
  7. Kennedy AR: The Bowman-Birk inhibitor from soybeans as an anticar- cinogenic agent. Am J Clin Nutr 68(Suppl.), 1406S-1412S, 1998.
  8. Du X, Beloussow K, and Shen W: Bowman-Birk protease inhibitor and its palmitic acid conjugate prevent 7, 12 dimethylbenz(a)anthracene in- duced transformation in culture mouse mammary glands. Cancer Lett 164, 135-141, 2001.
  9. Witschi H and Espiritu I: Development of tobacco smoke-induced lung tumors in mice fed Bowman-Birk protease inhibitor concentrate (BBIC). Cancer Lett 183, 141-146, 2002.
  10. Kashiwagi K, Virgona N, Yamada J, Sato A, Ota M, et al.: Bowman-Birk protease inhibitor from soybeans enhances cisplatin-induced cytotoxicity in human mesothelioma cells. Exp Ther Med 2, 719-724, 2011.
  11. Yavelow J, Collins M, Birk Y, Troll W, and Kennedy AR: Nanomolar con- centration of Bowman-Birk soybean protease inhibitor suppresses x-ray- induced transformation in vitro. Proc Natl Acad Sci (USA) 86, 9871-9875, 1985.
  12. Lippman SM and Matrisian LM: Protease inhibitors in oral carcinogenesis and chemoprevention. Clin Cancer Res 6, 4599-4603, 2000.
  13. USA patent number 7696173: Compositions Comprising Bowman-Birk Protease Inhibitors and Variants Thereof. Available online: http://www. patentgenius.com/patent/7696173.html
  14. Tareq A-A:. Plant Lectins. Poisonous Plants Homepage: Animal Sci- ence at Cornell University. Available online: http://www.ansci.cornell. edu/plants/toxicagents/lectins.html
  15. Kiss R, Camby I, Duckworth D, De-Decker R, and Salmon I: In vitro influ- ence of Phaseolus vulgaris, Griffonia simplicifolia, Concavalin A, wheat germ and peanut agglutinins on HCT-15, LoVo and SW 837 human color- rectal cancer cell growth. Gut 40, 253-261, 1997.
  16. González de Mejía E and Prisecaru VI:. Lectins as Bioactive Plant Proteins: A Potential in Cancer Treatment. Crit Rev Food Sci Nutr 45, 425-445, 2005.
  17. Ferriz-Martinez RA, Torres-Arteaga IC, Blanco-Labra A, and Garcia-Gasca T: The role of plant lectins in cancer treatment. In: The New Approaches in the Treatment of Cancer, Mejia C and Navarro S (eds.). Nova Science Publishers, NY, USA, 2010, pp. 71-89.
  18. Lyu S, Choi SH, Park WB, and Kim W: Involvement of caspase-3 in apoptosis induced by Viscum album var. coloratum agglutinin in HL-60 cells. Biosci Biothecnol. Biochem 65, 534-541, 2001.
  19. Pryme IF and Bardocz S: Anti-cancer therapy: Diversion of polyamines in the gut. Eur J Gastroenterol Hepatol 13, 1041-1046, 2001.
  20. Lyu S, Choi SH, and Park WB: Korean mistletoe lectin-induced apoptosis in hepatocarcinoma cells is associated with inhibition of telomerase via mitochondrial controlled pathway independent of p-53. Arch Pharm Res 25, 93-101, 2002.
  21. Campos J, Martínez-Gallardo N, Mendiola-Olaya E, and Blanco-Labra A: Purification and partial characterization of a proteinase inhibitor from Tepary bean (Phaseolus acutifolius) seeds. J Food Biochem 21, 203-218, 1997.
  22. García-Gasca T, Salazar-Olivo LA, Mendiola-Olaya E, and Blanco-Labra A:The effects of a protease inhibitor from Tepary bean (Phaseolus acutifolius) on in vitro cell proliferation and cell adhesion of transformed cells. Toxicol In Vitro 16, 229-233, 2002.
  23. Bradford M: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248-254, 1976.
  24. Jaffé W: Hemagglutinins (lectins). In: Toxic Constituents of Plant Food- stuffs. New York: Academic Press, 1980, pp. 73-102.
  25. Schwertz G and Takenaka Y: Spectrophotometric determination of trypsin and chymotrypsins activity. Biochim Biophys Acta 16, 571-575, 1955.
  26. Gerard C: Purification of glycoproteins. In: Guide to Protein Purification, Deutscher MP (ed.). San Diego, CA: Academic Press, 1990, pp. 535-536.
  27. Laemmli UK: Cleavage of structural proteins during the assembly of the head bacteriophage T4. Nature 227, 680-685, 1970.
  28. García-Gasca T, Paz-González V, Moncada-Álvarez M, Blanco-Labra A, and Salazar-Olivo L: Colorimetric quantitation of in vitro cell density us- ing carmine a chromosome-specific stain. Toxicol In Vitro 16, 573-579, 2002.
  29. Ignotz RA and Messague J: Transforming growth factor β stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 261, 4337-4345, 1986.
  30. Hawkes SP, Li H, and Taniguchi GT: Zymography and reverse zymography for detecting MMPs and TIMPs. In: Matrix Metalloproteinase Protocols. Methods in Molecular Biology (2nd ed.), Clark IM (ed.), and Young DA and Rowan AD (consulting eds.). New York: Humana Press, 2010, pp. 257-269.
  31. Pusztai A, Watt WB, and Stewart JC: Erithro-and lymphoaglglutinins of Phaseolus acutifolius. Phytochem 26, 1009-1013, 1987.
  32. Pratt RC, Singh NK, Shade RE, Murdock LL, and Bressan RA: Isolation and partial characterization of a seed lectin from tepary bean that delays bruchid beetle development. Plant Physiol 93, 1453-1459, 1990.
  33. Vargas-Albores F, de la Fuente G, Agundis C, and Córdoba F: Purification and characterization of a lectin from Phaseolus acutifolius var. latifolius. Prep Biochem 17, 379-396, 1987.
  34. Reynoso-Camacho R, Gonzalez de Mejia E, and Loarca-Piña G: Purifica- tion and acute toxicity of a lectin extracted from Tepary bean (Phaseolus acutifolius). Food Chem Toxicol 41, 21-27, 2003.
  35. Castillo-Villanueva A, Caballero-Ortega H, Abdullaev-Jafarova F, Ganfias Y, Jiménez-Martínez M, et al.: Lectin from Phaseolus acutifolius var. es- cumite: chemical characterization, sugar specificity, and effect on human T-lymphocytes. J Agric Food Chem 55, 5781-5787, 2007.
  36. de Mejía EG, Hankin C, Paredes-López O, and Shannon L: The lectins and lectin-like proteins of Tepary beans (Phaseolus acutifolius) and Tepary- common bean (Phaseolus vulgaris) hybrids. J Food Biochem 14, 117-126, 1990.
  37. Sharon N: Lectin-carbohidrate complexes of plants and animals: an atomic view. TIBS 18, 221-226, 1996.
  38. Sharon N and Lis H: History of lectins: from hemagglutinins to biological recognition molecules. Glycobiology 14, 53R-62R, 2004.
  39. Won-Ho K, Won BP, Bin G, and Myeong HJ: Critical role of reactive oxygen species and mitochondrial membrane potential in Korean mistletoe lectin-induced apoptosis in human hepatocarcinoma cells. Mol Pharmacol 66, 1383-1396, 2004.
  40. Petrossian K, Banner LR, and Oppenheimer SB: Lectin binding and effects in culture on human cancer and non-cancer cell lines: Examination of issues of interest in drug design strategies. Acta Histochem 109, 491-500, 2007.
  41. Valadez-Vega C, Guzmán-Partida AM, Soto-Cordova FJ, Álvarez-Manilla G, Morales-González JA, et al.: Purification, biochemical characterization, and bioactive properties of a lectin purified from the seeds of white tepary bean (Phaseolus acutifolius variety Latifolius). Molecules 16, 2561-2582, 2011.
  42. Valadez-Vega C, Alvarez-Manilla G, Riverón-Negrete L, García-Carrancá A, Morales-González JA, et al.: Detection of cytotoxic activity of lectin on human colon adenocarcinoma (Sw480) and epithelial cervical carcinoma (C33-A). Molecules 16, 2107-2118, 2011.
  43. Benaud CM, Oberst M, Dickson RB, and Lin CY: Deregulated activation of matriptase in breast cancer cells. Clin Exp Metastasis 19, 639-649, 2002.
  44. Uhland K: Matriptase and its putative role in cancer. Cell Mol Life Sci 63, 2968-2978, 2006.
  45. Pandey R, Patil N, and Rao M: Proteases and protease inhibitors: impli- cations in antitumorogenesis and drug development. Int J Hum Genet 7, 67-82, 2007.
  46. Castro-Guillén JL, Garcia-Gasca T, and Blanco-Labra A: Protease in- hibitors as anticancer agents. In: The New Approaches in the Treatment of Cancer, Mejia C and Navarro S (eds.). Nova Science Publishers, Inc., NY, USA, 2010, pp. 91-124.
  47. Ghosh S, Brown R, Jones JC, Ellerbroek SM, and Stack MS: Urinary- type plasminogen activator (uPA) expression and uPA receptor localization are regulated by α3β1 integrin in oral keratinocytes. J Biol Chem 275, 23869-23876, 2000.
  48. Ray J, and Stetler-Stevenson W: Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO J. 14, 908-917, 1995.
  49. Woessner JF Jr:. The matrix metalloproteinase family. In: Matrix Metallo- proteinases, Parks WC and Mecham RP (eds.). San Diego, CA: Academic Press, 1998, Pp. 1-13.
  50. Bodey B, Bodey JB, Siegel SE, and Kaiser HF: Matrix metalloproteinase expression in malignant melanomas: tumor-extracellular matrix interac- tions in invasion and metastasis. In Vivo 15, 57-64, 2001.
  51. Riikonen T, Westermarck J, Koivisto L, Broberg A, Kahari VM, et al.: Integrinα2β1 is a positive regulator of collagenase (MMP-1) and collagenα1 (I) gene expression. J Biol Chem 270, 13548-13552, 1995.
  52. Koblinski JE, Ahram M, and Sloana BF: Unraveling the role of proteases in cancer. Clin Chim Acta 291, 113-135, 2000.
  53. Kleiner DE and Stetler-Stevenson WG: Matrix metalloproteinases and metastasis. Cancer Chemother. Pharmacol 43(Suppl.), S42-S51, 1999.
  54. Yin S, Lockett J, Meng Y, Biliran H Jr, Blouse GE, et al.: Maspin re- tards cell detachment via a novel interaction with the urokinase-type plas- minogen activator/urokinase-type plasminogen activator receptor system. Cancer Res 66, 4173-4181, 2006.
  55. Moy LY and Billings PC: A proteolytic activity in a human breast cancer cell line which is inhibited by the anticarcinogenic Bowman-Birk protease inhibitor. Cancer Lett 85, 205-210, 1994.
  56. Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M; et al: Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J 16, 2319-2332, 1997.
  57. Ware JH, Wan XS, Rubin H, Schechter NM, and Kennedy AR: Soybean Bowman-Birk protease inhibitor is a highly effective inhibitor of human mast cell chymase. Arch Biochem Biophys 344, 133-138, 1997.
  58. Chambers AF and Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst 89, 1260-1270, 1997.
  59. Kennedy AR and Wan XS: Effects of the Bowman-Birk inhibitor on growth, invasion, and clonogenic survival of human prostate epithelial cells and prostate cancer cells. Prostate 50, 125-133, 2002.